INSP vs RMD
INSP: Inspire Medical Systems manufactures implantable nerve stimulation devices that treat obstructive sleep apnea without surgery or continuous positive airway pressure (CPAP). RMD: ResMed develops cloud-connected software platforms and digital devices for out-of-hospital care, spanning sleep apnea management, COPD treatment, and residential care operations.
Side-by-side fundamentals
| Metric | INSP | RMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $50.40 | $192.91 | |
| Market cap as of 2026-07-23 | $1.5B | $28.2B | |
| P/E as of 2026-07-23 | 11.06 | 18.56 | INSP lower |
| PEG as of 2026-07-23 | 0.11 | 1.15 | INSP lower |
| Net margin as of 2026-07-23 | +14.3% | +27.4% | RMD higher |
| Gross margin as of 2026-07-23 | +85.8% | +61.6% | INSP higher |
| Operating margin as of 2026-07-23 | +5.2% | +34.2% | RMD higher |
| ROE as of 2026-07-23 | +18.0% | +24.4% | RMD higher |
| ROA as of 2026-07-23 | +15.3% | +18.0% | RMD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.10 | INSP lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.9% | +10.3% | RMD higher |
| Revenue CAGR (3y) SEC XBRL | +30.8% | +12.9% | INSP higher |
| Dividend yield as of 2026-07-23 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.66 | 0.76 | |
| 1-year return as of 2026-07-22 close | -61.1% | -27.9% | RMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.